10.46
+7.72%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eupraxia Pharmaceuticals
Its shares trade on Toronto Stock Exchange under the ticker EPRX.TO. It has been listed since 9 March 2021.
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release alternatives to approved drugs. The Company’s principal business is the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). The primary active ingredient of the EP-104 products consists of a solid core of fluticasone propionate (FP) coated with an outer layer of polyvinyl alcohol (PVA). Its lead product candidate is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms and is used corticosteroid with systemic safety record. EP-104 is in Phase Ib/IIa clinical development.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Mar 2021
- Employees
- 21
Leadership
Pay as last reported
- Dr. Simon PimstoneIndependent Chairman of the BoardC$127,248
- Dr. James HelliwellChief Executive Officer, Director, since 2012C$1.4m
- Mr. Alexander RothwellChief Financial Officer, since 2025C$2.5m
- Dr. Amanda MaloneChief Operating and Scientific Officer, since 2023C$776,949
- Mr. Paul BrennanChief Business OfficerC$445,821
- Dr. Mark KowalskiChief Medical OfficerC$718,010
- Mr. Joseph FreedmanIndependent DirectorC$193,911
- Mr. Paul GeyerIndependent DirectorC$108,851
- Dr. Richard GlickmanIndependent DirectorC$115,056
- Mr. John MontalbanoIndependent DirectorC$115,056
- Dr. Michael WilminkIndependent DirectorC$108,851
- Mr. Adam PeelerInvestor relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Victoria, British Columbia with 21 employees
- Focused on developing locally delivered, extended-release drug alternatives
- Lead product candidate EP-104IAR in Phase Ib/IIa clinical development
Weaknesses
- Company went public via IPO in 2021
- Limited employee count of 21 full-time staff
- Product candidate EP-104IAR is in early clinical development phase
Opportunities
- Addressing unmet medical needs for knee osteoarthritis pain relief
- Potential market demand for long-lasting pain relief alternatives
- Development of EP-104 for eosinophilic esophagitis symptoms
Threats
- Dependence on early-stage clinical development for EP-104IAR
- Competition in the biotechnology sector for drug delivery technologies
- Risk associated with regulatory approval for new drug candidates
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.